Prof. Haya Lorberboum-Galski
Chairwoman, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School
, Biochemistry & Molecular Biology, IMRIC
Head, Committee for Research and Foreign Affairs, IMRIC
Prof. Haya LorberboumGalski was born in Lignitza, Poland, and immigrated to Israel as a baby. Following her army service (where she served as an officer), she received her Ph.D. in Biochemistry from the Hebrew University. She was a postdoctoral fellow at the Molecular Biology Laboratory, NCI, NIH.
Her research interests focus on developing reagents for targeted human therapy (chimeric/fusion proteins), cancer, metabolic diseases,immune responses and mechanisms of apoptosis. She has published over 60 publications in peerreviewed journals, as well as review articles, and edited a book on chimeric proteins. She currently heads the IMRIC research committee at the Faculty of Medicine. Haya is the proud mother of two wonderful children, one of whom now is serving in the army.
"Since 1989, I have been part of the Hebrew University Faculty of Medicine, involved in my own research on developing reagents for targeted human therapy. But my biggest role is my work at IMRIC, where I help direct the operations of IMRIC and its dynamic team of researchers. Their individual work and their collaborations with other researchers in Canada are making a major contribution toward finding solutions to the major medical problems we face today. I am fortunate to be a part of that team."
Research focus: Development of specific immunosuppressive agents. Cancer: mechanisms and treatment. Immune responses - mechanisms and pathways.
1986: Ph.D., Biochemistry, the Hebrew University of Jerusalem
The annual Kaye Innovation Awards at the Hebrew University were established in 1993 by Isaac Kaye, a pharmaceutical chemist who has become very successful in translating novel ideas into marketed profit-generating products. Since their inception, the awards have earned a prestigious reputation. The prizes are awarded annually for any innovation that shows potential for bringing profit or savings to the University principally through royalties.
She introduced her presentation, explaining that she would take the audience through the journey of how she is working to develop a cure, and the process that she must follow in the hopes that she will one day reach human trial.
NOTE: Dr. Haya Lorberboum-Galski, Chairperson of The Institute for Medical Research Israel-Canada (IMRIC) at The Hebrew University of Jerusalem, was a key member of the research team behind this work.
The Israeli drug developer sees potential initial sales of over $1 billion for Cabaletta, which could be marketed by 2017.
BioBlast Pharma Ltd.(Nasdaq:ORPN) announced promising interim results on Tuesday from its Phase II study of its leading treatment, Cabaletta, with 25 patients suffering from oculopharyngeal muscular dystrophy (OPMD). Due to the success of the open label HOPEMD trial, the Israeli drug developer seeks to fast track a Phase III study in 2016.
Cabaletta showed statistically significant improvements for patients in several tests, while also hitting its marks for safety and tolerability. The study was conducted at two research centers -- Hadassah-Hebrew University Medical Center in Jerusalem and Montreal Neurological Institute at McGill University in Canada.
“The interim results for OPMD, specifically with respect to dysphagia and muscle strength and function, give us insight into the potential of Cabaletta for use in other protein aggregation-related diseases, such as spinocerebellar ataxia type 3 (SCA3 or Machado Joseph disease), another devastating hereditary disease in which we are planning a pivotal Phase 3 study in the US and EU,” said CEO Colin Foster.
There is currently no approved treatment for OPMD, a rare muscle-wasting disease characterized by swallowing difficulties. "There is a critical unmet need for patients with this rare disorder,” said Peter L. Saltonstall, the leader of the National Organization for Rare Disorders. "We are grateful to BioBlast and to the physicians and patients who have committed their time and resources to this important clinical trial."
BioBlast believes it may be able to get the treatment on the market by 2017, with initial sales potential of more than $1 billion. In pre-market trading on Nasdaq, BioBlast share price was up by over 20%.
Discussed collaborative medical research partnerships between Canada and Israel at IMRIC, the Institute for Medical Research Israel-Canada. Mrs. Johnston Visited Early Childhood Programs at Hebrew University.